Eric Angevin
Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses, Cancer Genomics and Diagnostics, CAR-T cell therapy research
Most-Cited Works
- → Immune-related adverse events with immune checkpoint blockade: a comprehensive review(2016)2,094 cited
- → Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming(2001)1,605 cited
- → Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial(2005)1,237 cited
- → Malignant effusions and immunogenic tumour-derived exosomes(2002)938 cited
- → High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial(2017)760 cited
- → Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells(2004)489 cited
- → Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects(2004)285 cited
- → Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection(2004)266 cited
- → Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)(2017)218 cited
- → Tumor-derived exosomes: a new source of tumor rejection antigens(2002)212 cited